THE DEAL, AT A GLANCE
From the announcementBeam Therapeutics
01What it doesThe new capital is framed around Advance BEAM-101 SCD and BEAM-302 AAT deficiency through Phase 2 trials.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedBeam Therapeutics raised $200M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersBeam Therapeutics is using Growth Round capital to advance base editing gene therapies for sickle cell disease and AAT deficiency through Phase 2 trials.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Beam Therapeutics · Financing Record
Explore source-linked visual explanations for Beam Therapeutics. Unsupported claims are withheld while source review continues.
Record 1447 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →